Entropy Neurodynamics Limited Total Assets
Entropy Neurodynamics Limited total assets. Based on the latest financial reports, Entropy Neurodynamics Limited (ENP) holds total assets worth AU$8.38 Million AUD (≈ $5.93 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Entropy Neurodynamics Limited for the company's overall valuation and market capitalisation.
Total Assets of Entropy Neurodynamics Limited (2018–2026)
Total assets of Entropy Neurodynamics Limited from 2018 to 2026. This chart illustrates how Entropy Neurodynamics Limited's total assets have evolved over time, based on quarterly financial data. See today's stock price for Entropy Neurodynamics Limited for real-time trading data and today's change.
Entropy Neurodynamics Limited - Asset Composition Analysis
Entropy Neurodynamics Limited Total Assets Breakdown (June 2026)
Entropy Neurodynamics Limited total assets breakdown as of June 2026. Entropy Neurodynamics Limited's total assets of AU$8.38 Million consist of 96.7% current assets and 3.3% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 66.5% |
| Accounts Receivable | AU$2.09 Million | 24.9% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$183.04K | 2.2% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2018–2026)
This chart illustrates how Entropy Neurodynamics Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ENP net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Entropy Neurodynamics Limited's current assets represent 96.7% of total assets in 2026, an increase from 36.6% in 2018.
- Cash Position: Cash and equivalents constituted 66.5% of total assets in 2026, up from 17.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 56.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 24.9% of total assets.
Entropy Neurodynamics Limited Competitors by Total Assets
Key competitors of Entropy Neurodynamics Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Entropy Neurodynamics Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.94 | 9.08 | 9.72 |
| Quick Ratio | 7.94 | 9.08 | 9.72 |
| Cash Ratio | 0.00 | 4.33 | 0.00 |
| Working Capital | AU$7.09 Million | AU$5.65 Million | AU$15.43 Million |
Entropy Neurodynamics Limited - Advanced Valuation Insights
This section examines the relationship between Entropy Neurodynamics Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.10 |
| Latest Market Cap to Assets Ratio | 4.00 |
| Asset Growth Rate (YoY) | 25.8% |
| Total Assets | AU$8.38 Million |
| Market Capitalization | $33.52 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Entropy Neurodynamics Limited's assets at a significant premium (4.00x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Entropy Neurodynamics Limited's assets grew by 25.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Entropy Neurodynamics Limited (2018–2026)
The table below shows the annual total assets of Entropy Neurodynamics Limited from 2018 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-06-30 | AU$8.38 Million ≈ $5.93 Million |
+25.83% |
| 2025-06-30 | AU$6.66 Million ≈ $4.71 Million |
-10.60% |
| 2024-06-30 | AU$7.45 Million ≈ $5.27 Million |
+26.72% |
| 2023-06-30 | AU$5.88 Million ≈ $4.16 Million |
-56.80% |
| 2022-06-30 | AU$13.61 Million ≈ $9.63 Million |
-36.55% |
| 2021-06-30 | AU$21.46 Million ≈ $15.18 Million |
+227.96% |
| 2020-06-30 | AU$6.54 Million ≈ $4.63 Million |
+21.14% |
| 2019-06-30 | AU$5.40 Million ≈ $3.82 Million |
+1651.96% |
| 2018-06-30 | AU$308.26K ≈ $218.11K |
-- |
About Entropy Neurodynamics Limited
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 … Read more